The recent randomized STRONG-HF (Safety, Tolerability and Efficacy of Rapid Optimization, Helped by NT-proBNP testinG, of Heart Failure Therapies) study underlined the feasibility and benefit of rapid initiation and optimization of 3 concurrent GDMT agents versus usual care.84 The gene discussed is NPPB; the disease is heart failure.